Pacira Pharmaceuticals (PCRX) PT Set at $44.00 by Royal Bank of Canada
Several other equities research analysts also recently issued reports on PCRX. HC Wainwright set a $45.00 price target on Pacira Pharmaceuticals and gave the stock a buy rating in a report on Thursday. Oppenheimer restated a hold rating on shares of Pacira Pharmaceuticals in a report on Thursday. Canaccord Genuity restated a hold rating and issued a $32.00 price target on shares of Pacira Pharmaceuticals in a report on Friday, February 16th. Needham & Company LLC downgraded Pacira Pharmaceuticals from a buy rating to a hold rating and set a $55.00 price target for the company. in a report on Friday, February 16th. Finally, BidaskClub downgraded Pacira Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, January 6th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Pacira Pharmaceuticals currently has an average rating of Hold and an average target price of $45.29.
Pacira Pharmaceuticals (NASDAQ PCRX) traded up $0.55 during midday trading on Thursday, reaching $33.25. The company had a trading volume of 723,872 shares, compared to its average volume of 1,120,000. The company has a market capitalization of $1,350.00, a P/E ratio of -30.50 and a beta of 1.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a fifty-two week low of $29.35 and a fifty-two week high of $52.47.
In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.60% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of PCRX. Millennium Management LLC acquired a new position in shares of Pacira Pharmaceuticals during the fourth quarter worth about $24,644,000. Mesirow Financial Investment Management Equity Management acquired a new position in shares of Pacira Pharmaceuticals during the third quarter worth about $14,671,000. Stonepine Capital Management LLC acquired a new position in shares of Pacira Pharmaceuticals during the third quarter worth about $14,089,000. Epoch Investment Partners Inc. boosted its position in shares of Pacira Pharmaceuticals by 195.7% during the third quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after buying an additional 354,728 shares during the period. Finally, Consonance Capital Management LP boosted its position in shares of Pacira Pharmaceuticals by 16.1% during the fourth quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock worth $73,147,000 after buying an additional 222,200 shares during the period.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.